Diisopropylethylamine → HCID 178522406, compound
Reaction equation
[CH:1]1([C:4]2[CH:8]=[C:7]([NH:9][C:10]3[C:11]4[CH2:26][CH2:25][CH2:24][C:12]=4[N:13]=[C:14]([N:16]4[CH2:20][CH2:19][CH2:18][CH:17]4[C:21](O)=[O:22])[N:15]=3)[NH:6][N:5]=2)[CH2:3][CH2:2]1.[N:27]1[CH:32]=[C:31]([NH2:33])[CH:30]=[N:29][CH:28]=1.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CCN(C(C)C)C(C)C>CN(C=O)C.O>[CH:1]1([C:4]2[CH:8]=[C:7]([NH:9][C:10]3[C:11]4[CH2:26][CH2:25][CH2:24][C:12]=4[N:13]=[C:14]([N:16]4[CH2:20][CH2:19][CH2:18][CH:17]4[C:21]([NH:33][C:31]4[CH:32]=[N:27][CH:28]=[N:29][CH:30]=4)=[O:22])[N:15]=3)[NH:6][N:5]=2)[CH2:3][CH2:2]1Participants
Reactant 4
Product 1
Reagents, catalysts & solvents 2
Procedure
To a solution of 1-(4-(3-cyclopropyl-1H-pyrazol-5-ylamino)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-yl)pyrrolidine-2-carboxylic acid (300 mg, 0.847 mmol) in DMF (4 mL) was added pyrimidin-5-amine (201 mg, 2.11 mmol), HATU (386 mg, 1.016 mmol) and DIPEA (0.24 mL, 1.4 mmol). The reaction mixture was allowed to stir at RT for 16 h. The reaction mixture was diluted with water (40 mL) and extracted with EtOAc (2×25 mL). The organic layer was washed with water (8×30 mL) and dried over anhydrous sodium sulfate. Removal of EtOAc under reduced pressure gave a crude product that was purified by reverse phase HPLC to afford 11 mg of 1-(4-(3-cyclopropyl-1H-pyrazol-5-ylamino)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-yl)-N-(pyrimidin-5-yl)pyrrolidine-2-carboxamide as free base. 1H NMR (400 MHz, CD3OD, formate salt) δ (ppm): 0.58-0.67 (m, 2H), 0.80-0.94 (m, 2H), 1.70-1.78 (m, 1H), 2.09-2.21 (m, 4H), 2.22-2.42 (m, 2H), 2.78-2.81 (m, 2H), 2.82-2.95 (m, 2H), 3.60-2.70 (m, 1H), 3.78-3.88 (m, 1H), 4.78 (dd, 1H), 6.08 (s, 1H), 8.84 (s, 1H), 8.89 (s, 2H). Separation by chiral HPLC provided enantiomers 7a and 7b.
Workup
- extractionextracted with EtOAc (2×25 mL)
- washThe organic layer was washed with water (8×30 mL)
- dry with materialdried over anhydrous sodium sulfate
- customRemoval of EtOAc under reduced pressure
- customgave a crude product that
- customwas purified by reverse phase HPLC
Sources & evidence
- ORD record
- ord-54615688604249548ca1b81746094979
- Source dataset
- uspto-grants-2016_08
- Patent number
- US09422267B2
Reaction notes
Loading…